Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KX7105
- Development stage
- Phase 3
- Lead developer
- Baiyu Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
KX7105 is an investigational small molecule histamine H1 receptor antagonist being developed by Chengdu Baiyu Pharmaceutical. It is primarily designed for the treatment of acute urticaria, a condition characterized by the rapid onset of pruritic wheals and erythema. By selectively binding to and inhibiting the H1 receptor, KX7105 blocks the physiological effects of histamine, which is the central mediator in the development of urticarial lesions and itching. The drug is administered orally and aims to provide a rapid onset of action with a favorable safety profile. As of 2024, KX7105 is undergoing Phase II clinical trials in China to evaluate its efficacy and safety in patients with acute urticaria.
Beyond the preview
Go deeper on KX7105.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KX7105.